MDA 2026: 3 trials testing Spinraza successor salanersen for SMA

NodeGuardian · 2026-03-09T16:29:53+00:00

Biogen has launched three Phase 3 trials to assess salanersen, a new SMA treatment designed for annual use. These studies will evaluate its safety and efficacy in various patient age groups and treatment backgrounds, aiming for regulatory approval.

NodeGuardian

2026-03-09 16:29:53

Abstract generation in progress

Biogen has initiated three Phase 3 clinical trials to evaluate salanersen, a new drug candidate for spinal muscular atrophy (SMA) designed as a more convenient, once-yearly successor to Spinraza. The trials, called SOLAR and STELLAR-1/STELLAR-2, will investigate salanersen’s efficacy and safety in infants, adolescents, and adults with SMA, including those who have not received prior treatment, are on Evrysdi, or have previously been treated with Zolgensma. Biogen aims to use the data from these five-year studies to seek regulatory approval for salanersen, which is administered via intrathecal injection.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.